Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Clin Neuropharmacol. 2010 Jan-Feb;33(1):5-10. doi: 10.1097/WNF.0b013e3181b7926f.
Clin Neuropharmacol. 2010.
PMID: 19855267
Clinical Trial.